69 related articles for article (PubMed ID: 22405049)
1. Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Persson E
Thromb Res; 2012 May; 129 Suppl 2():S51-3. PubMed ID: 22405049
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Schaub RG
Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
4. Reversible acylation of factor Xa as a potential therapy for hemophilia.
Lin PH; Laibelman AM; Sinha U
Thromb Res; 1997 Nov; 88(4):365-72. PubMed ID: 9526960
[TBL] [Abstract][Full Text] [Related]
5. Acquired hemophilia: diagnosis and management.
Zakarija A; Green D
Curr Hematol Rep; 2002 Sep; 1(1):27-33. PubMed ID: 12901122
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab promotes factor Xa generation on endothelial cells.
Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
8. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
Ton-That TT; Doron D; Pollard BS; Bacher J; Pollard HB
Nat Biotechnol; 2000 Mar; 18(3):289-95. PubMed ID: 10700143
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.
Carr ME; Martin EJ
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):661-74. PubMed ID: 15350168
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
Iizuka A; Kuwashima M; Nagao T
Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
[No Abstract] [Full Text] [Related]
11. Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Ebert M; Raquet E; Schweisgut S; Schmidt PM; Weimer T
Blood Cells Mol Dis; 2021 Jul; 89():102570. PubMed ID: 33962291
[TBL] [Abstract][Full Text] [Related]
12. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII.
Mertens K; van Wijngaarden A; Bertina RM; Veltkamp JJ
Thromb Haemost; 1985 Oct; 54(3):650-3. PubMed ID: 3937262
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.
O'Brien DP; Giles AR; Tate KM; Vehar GA
J Clin Invest; 1988 Jul; 82(1):206-11. PubMed ID: 3134399
[TBL] [Abstract][Full Text] [Related]
14. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
15. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.
Young G; Blain R; Nakagawa P; Nugent DJ
Haemophilia; 2006 Nov; 12(6):598-604. PubMed ID: 17083509
[TBL] [Abstract][Full Text] [Related]
16. Factors that influence the bleeding phenotype in severe hemophilic patients.
Rendo P; Shafer F; Korth-Bradley JM; Sivamurthy K; Korin J
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):683-90. PubMed ID: 24056291
[TBL] [Abstract][Full Text] [Related]
17. Normalization of the haemostatic plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles.
Hong yu Ni; Giles AR
Thromb Haemost; 1992 Feb; 67(2):264-71. PubMed ID: 1621248
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutics for hemophilia and other bleeding disorders.
Callaghan MU; Sidonio R; Pipe SW
Blood; 2018 Jul; 132(1):23-30. PubMed ID: 29769259
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors in mild/moderate haemophilia A: an update.
Franchini M; Salvagno GL; Lippi G
Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
[TBL] [Abstract][Full Text] [Related]
20. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
